Abstract
Correction: Reduction of Maternal Mortality with Highly Active Antiretroviral Therapy in a Large Cohort of HIV-Infected Pregnant Women in Malawi and Mozambique
Highlights
Maternal death classically encompasses the period of pregnancy until 42 days after the termination of gestation, and is attributable to causes related or aggravated by pregnancy or its management
In 2010, for example, 287,000 maternal deaths were reported globally, of which 56% occurred in Sub-Saharan Africa, where the average Maternal Mortality Rate (MMR) was 500 deaths per 100,000 live births with 10% of deaths occurring as a direct consequence of HIV infection [1]
We previously reported a significant association between extended antenatal Highly Active Antiretroviral Therapy (HAART) and reduced maternal mortality and improved pregnancy outcomes in a cohort of 3000 HIV-infected pregnant women followed in the program [3]
Summary
Maternal death classically encompasses the period of pregnancy until 42 days after the termination of gestation, and is attributable to causes related or aggravated by pregnancy or its management. Pregnancy related-deaths, are defined as maternal deaths occurring during the same time period irrespective of cause. Late maternal deaths encompass the period between 42 days post pregnancy up to one year within termination of gestation and include deaths from direct or indirect obstetric causes. Pregnancy is a condition which tends to worsen HIV infection and its co-morbidities Due to these differences in categorization and timing of maternal mortality, it is difficult for surveillance programs to gauge the impact of HIV on maternal mortality and the impact of pregnancy on HIV-related deaths. HIV-infection is a major contributor to maternal mortality in resource-limited settings. The Drug Resource Enhancement Against AIDS and Malnutrition Programme has been promoting HAART use during pregnancy and postpartum for Prevention-of-mother-to-child-HIV transmission (PMTCT) irrespective of maternal CD4 cell counts since 2002
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
